Engineering APIs to improve bioavailability

2021-03-15 - 2021-03

Therapeutic effectiveness of a drug depends upon its bioavailability - the fraction of an administered dose of an active pharmaceutical ingredient (API) that reaches the systemic circulation. Physicochemical characterization of an API is a critical tool of an Investigational New Drug (IND), enabling development and the selection of the optimum drug candidate.

Causes of low bioavailability

2021-03-05 - 2021-03

Orally administered drugs must pass through the intestinal wall and then the portal circulation to the liver; both are common sites of first-pass metabolism (metabolism that occurs before a drug reaches systemic circulation). Thus, many drugs may be metabolized before adequate plasma concentrations are reached. Low bioavailability is most common with oral dosage forms of poorly water-soluble, slowly absorbed drugs.

Assessing bioavailability

2021-02-19 - 2021-02

The most reliable measure of a drug’s bioavailability is AUC. AUC is directly proportional to the total amount of unchanged drug that reaches systemic circulation. Drug products may be considered bioequivalent in extent and rate of absorption if their plasma concentration curves are essentially superimposable.

Brochure Form

Abstracts enquiry

Registration enquiry

Contact Enquiry

Sponsors / Advertising

Phone

WhatsApp

Useful Links

News

Engineering APIs to improve bioavailability

Causes of low bioavailability

Assessing bioavailability

Newsletter

Brochure

Bioavailability and Bioequivalence

Brochure Form

Engineering APIs to improve bioavailability

Causes of low bioavailability

Assessing bioavailability